On Monday, Pacific Biosciences of California Inc (NASDAQ: PACB) was 6.96% up from the session before settling in for the closing price of $2.30. A 52-week range for PACB has been $1.16 – $10.65.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 24.48% over the last five years. When this article was written, the company’s average yearly earnings per share was at -12.49%. With a float of $259.36 million, this company’s outstanding shares have now reached $267.74 million.
The firm has a total of 796 workers. Let’s measure their productivity. In terms of profitability, gross margin is 19.6%, operating margin of -166.74%, and the pretax margin is -218.04%.
Pacific Biosciences of California Inc (PACB) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Pacific Biosciences of California Inc stocks. The insider ownership of Pacific Biosciences of California Inc is 4.83%, while institutional ownership is 80.11%. The most recent insider transaction that took place on Sep 30 ’24, was worth 34,065. In this transaction an insider of this company sold 19,782 shares at a rate of $1.72, taking the stock ownership to the 695,654 shares. Before that another transaction happened on Sep 30 ’24, when Company’s Officer proposed sale 19,782 for $1.72, making the entire transaction worth $34,061.
Pacific Biosciences of California Inc (PACB) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -12.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.00% during the next five years compared to -9.76% drop over the previous five years of trading.
Pacific Biosciences of California Inc (NASDAQ: PACB) Trading Performance Indicators
You can see what Pacific Biosciences of California Inc (PACB) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 16.57. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.46, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.68 in one year’s time.
Technical Analysis of Pacific Biosciences of California Inc (PACB)
Analysing the last 5-days average volume posted by the [Pacific Biosciences of California Inc, PACB], we can find that recorded value of 17.83 million was better than the volume posted last year of 9.55 million. As of the previous 9 days, the stock’s Stochastic %D was 65.41%. Additionally, its Average True Range was 0.26.
During the past 100 days, Pacific Biosciences of California Inc’s (PACB) raw stochastic average was set at 83.33%, which indicates a significant increase from 74.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 86.23% in the past 14 days, which was lower than the 118.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.88, while its 200-day Moving Average is $2.57. Now, the first resistance to watch is $2.56. This is followed by the second major resistance level at $2.65. The third major resistance level sits at $2.85. If the price goes on to break the first support level at $2.27, it is likely to go to the next support level at $2.07. Should the price break the second support level, the third support level stands at $1.98.
Pacific Biosciences of California Inc (NASDAQ: PACB) Key Stats
There are 272,529K outstanding shares of the company, which has a market capitalization of 629.38 million. As of now, sales total 200,520 K while income totals -306,740 K. Its latest quarter income was 36,010 K while its last quarter net income were -173,320 K.
